1-3 of 3
Michel-Olivier Gratton
Close
Sort by
Journal Articles

Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study

Adi J. Klil-Drori, MD, Hui Yin, MSc, Laurent Azoulay, PhD, Alexa Del Corpo, Michael Harnois, Michel-Olivier Gratton, Lambert Busque, MD, Sarit Assouline, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 315.
https://doi.org/10.1182/blood.V130.Suppl_1.315.315
Published: 2017
Journal Articles

Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia

Adi J. Klil-Drori, MD, Laurent Azoulay, PhD, Hui Yin, MSc, Alexa Del Corpo, Michaël Harnois, MSc, Michel-Olivier Gratton, MSc, Ines Chamakhi, MD, Robert Delage, MD MSc, FRCP, Luigina Mollica, MD PhD, Pierre Laneuville, MD FRCPC, Harold J. Olney, MD CM, Lambert Busque, MD, Sarit E. Assouline, MDMSc
Journal: Blood
Blood (2016) 128 (22): 3072.
https://doi.org/10.1182/blood.V128.22.3072.3072
Published: 2016
Journal Articles

Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia

Adi J Klil-Drori, MD, Laurent Azoulay, PhD, Hui Yin, MSc, Michel-Olivier Gratton, MSc, Michaël Harnois, MSc, Ines Chamakhi, MD, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Luigina Mollica, MD FRCPC, PhD, Harold J. Olney, MD CM, Lambert Busque, MD, Sarit E. Assouline, MDMSc
Journal: Blood
Blood (2015) 126 (23): 2778.
https://doi.org/10.1182/blood.V126.23.2778.2778
Published: 2015